In:
Journal of Multiple Sclerosis and Neuroimmunology, Korean Society of Neuroimmunology, Vol. 14, No. 1 ( 2023-06-30), p. 51-55
Abstract:
Background: In the present era of rapidly evolving treatment options, there is a need for better understanding of the epidemiology and current management of patients with multiple sclerosis (MS). A survey was conducted to determine the epidemiologic characteristics and the current treatment status of patients with MS in Korea.Methods: In April 2022, we collected data on patients with MS, including number participating in follow up, sex ratio, current disease modifying treatment (DMT), and disability status (Expanded Disability Status Score, EDSS) from 30 major MS centers in Korea.Results: A total of 1,290 patients with MS was identified, with a female to male ratio of 2.4:1. Geographically, 1,047 patients (81%) were being monitored at hospitals in the capital regions (Seoul, Incheon, and Gyeonggi-do), while 243 (19%) were receiving care at hospitals outside the capital regions. There were 1,199 patients on DMTs, with 876 (73%) taking drugs with moderate efficacy and 264 (22%) taking drugs with high efficacy. Patients with current EDSS score greater than 3.0 and 5.5 numbered 242 (20%) and 105 (9%), respectively.Conclusion: The hospital-based prevalence survey revealed the number and geographical distribution of patients with MS in Korea.
Type of Medium:
Online Resource
ISSN:
2733-8290
,
2951-2972
DOI:
10.59578/jmsni.2023.14.1.51
Language:
English
Publisher:
Korean Society of Neuroimmunology
Publication Date:
2023
Bookmarklink